Saltar al contenido
Merck

Thyroid hormone and thyromimetics inhibit myelin and axonal degeneration and oligodendrocyte loss in EAE.

Journal of neuroimmunology (2021-01-11)
P Chaudhary, G H Marracci, E Calkins, E Pocius, A L Bensen, T S Scanlan, B Emery, D N Bourdette
RESUMEN

We have previously demonstrated that thyromimetics stimulate oligodendrocyte precursor cell differentiation and promote remyelination in murine demyelination models. We investigated whether a thyroid receptor-beta selective thyromimetic, sobetirome (Sob), and its CNS-targeted prodrug, Sob-AM2, could prevent myelin and axonal degeneration in experimental autoimmune encephalomyelitis (EAE). Compared to controls, EAE mice receiving triiodothyronine (T3, 0.4 mg/kg), Sob (5 mg/kg) or Sob-AM2 (5 mg/kg) had reduced clinical disease and, within the spinal cord, less tissue damage, more normally myelinated axons, fewer degenerating axons and more oligodendrocytes. T3 and Sob also protected cultured oligodendrocytes against cell death. Thyromimetics thus might protect against oligodendrocyte death, demyelination and axonal degeneration as well as stimulate remyelination in multiple sclerosis.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Anti-Aspa/Nur7 Antibody, from rabbit, purified by affinity chromatography
Sigma-Aldrich
Sob-AM2, ≥98% (HPLC)
Sigma-Aldrich
Anti-CNPase Antibody, clone 11-5B, clone 11-5B, Chemicon®, from mouse